Literature DB >> 21850469

Widespread expressions of immunoglobulin superfamily proteins in cancer cells.

Gregory Lee1, Mingang Zhu, Bixia Ge, Suzanne Potzold.   

Abstract

RP215 monoclonal antibody (Mab) was shown to recognize a carbohydrate-associated epitope of cancer cell-expressed glycoproteins, known as CA215. Extensive MALDI-TOF MS analysis was performed to search for the molecular identity of CA215. Besides immunoglobulin (Ig) heavy chains, homology to human T-cell receptors (TCR) and Ig-like cell adhesion molecules was also detected. By using RT-PCR and cDNA sequencing, it was observed that as many as 80% of cancer cell lines showed significant levels of gene expressions of TCR-α and TCR-β. Selected Ig-like cell adhesion molecules such as CD47, CD54, CD58 and CD 147 were also highly expressed among all the cell lines tested. In contrast, co-receptors and co-stimulators of TCR such as CD3, CD4 and CD8 were rarely expressed demonstrating the non-functional nature of TCR in cancer cells. Results of immunohistochemical staining and Western blot assays of cancer cell lines as well as cancerous tissue sections were consistent with these observations. Anti-TCR and anti-human IgG antibodies were shown to induce complement-dependent cytotoxicity and apoptosis of cultured cancer cells indicating the surface nature of Ig-like proteins. Based on these experimental observations, it was hypothesized that the expressions of these immunoglobulin superfamily (IgSF) proteins may be relevant to the immune protection and proliferations of cancer cells during carcinogenesis or cancer progression. Surface-bound TCR-like proteins as well as immunoglobulins may be the potential targets for RP215-based anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21850469     DOI: 10.1007/s00262-011-1088-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  ProtLID, a Residue-Based Pharmacophore Approach to Identify Cognate Protein Ligands in the Immunoglobulin Superfamily.

Authors:  Eng-Hui Yap; Andras Fiser
Journal:  Structure       Date:  2016-11-23       Impact factor: 5.006

2.  Neuron-derived IgG protects neurons from complement-dependent cytotoxicity.

Authors:  Jie Zhang; Na Niu; Bingjie Li; Michael A McNutt
Journal:  J Histochem Cytochem       Date:  2013-08-26       Impact factor: 2.479

3.  Cancer IgG, a potential prognostic marker, promotes colorectal cancer progression.

Authors:  Hongpeng Jiang; Boxi Kang; Xinmei Huang; Yichao Yan; Shan Wang; Yingjiang Ye; Zhanlong Shen
Journal:  Chin J Cancer Res       Date:  2019-06       Impact factor: 5.087

4.  Lung cell membrane-coated nanoparticles capable of enhanced internalization and translocation in pulmonary epithelial cells.

Authors:  Md Golam Jakaria; Parand Sorkhdini; Dongqin Yang; Yang Zhou; Samantha A Meenach
Journal:  Int J Pharm       Date:  2021-12-22       Impact factor: 5.875

5.  Cancer cell-derived immunoglobulin G activates platelets by binding to platelet FcγRIIa.

Authors:  Shuo Miao; Dan Shu; Ying Zhu; Meng Lu; Qingsong Zhang; Youliang Pei; Ao-Di He; Rong Ma; Bixiang Zhang; Zhang-Yin Ming
Journal:  Cell Death Dis       Date:  2019-01-28       Impact factor: 8.469

6.  Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK.

Authors:  Yaohua Li; Yiran Deng; Yannan Zhao; Wei Zhang; Si Zhang; Li Zhang; Biyun Wang; Yingying Xu; She Chen
Journal:  Oncogene       Date:  2022-09-10       Impact factor: 8.756

7.  IgG expression in human colorectal cancer and its relationship to cancer cell behaviors.

Authors:  Na Niu; Jie Zhang; Tao Huang; Yingui Sun; Zhengshan Chen; Weining Yi; Christine Korteweg; Juping Wang; Jiang Gu
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

Review 8.  Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?

Authors:  Henning M Schramm
Journal:  J Cancer       Date:  2014-01-15       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.